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Abstract
E-cadherin is critical for the maintenance of tissue architecture due to its role in cell-cell adhesion. E-cadherin mutations are
the genetic cause of Hereditary Diffuse Gastric Cancer (HDGC) and missense mutations represent a clinical burden, due to
the uncertainty of their pathogenic role. In vitro and in vivo, most mutations lead to loss-of-function, although the causal
factor is unknown for the majority. We hypothesized that destabilization could account for the pathogenicity of E-cadherin
missense mutations in HDGC, and tested our hypothesis using in silico and in vitro tools. FoldX algorithm was used to
calculate the impact of each mutation in E-cadherin native-state stability, and the analysis was complemented with
evolutionary conservation, by SIFT. Interestingly, HDGC patients harbouring germline E-cadherin destabilizing mutants
present a younger age at diagnosis or death, suggesting that the loss of native-state stability of E-cadherin accounts for the
disease phenotype. To elucidate the biological relevance of E-cadherin destabilization in HDGC, we investigated a group of
newly identified HDGC-associated mutations (E185V, S232C and L583R), of which L583R is predicted to be destabilizing. We
show that this mutation is not functional in vitro, exhibits shorter half-life and is unable to mature, due to premature
proteasome-dependent degradation, a phenotype reverted by stabilization with the artificial mutation L583I (structurally
tolerated). Herein we report E-cadherin structural models suitable to predict the impact of the majority of cancer-associated
missense mutations and we show that E-cadherin destabilization leads to loss-of-function in vitro and increased
pathogenicity in vivo.
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Introduction
E-cadherin is a cell-cell adhesion glycoprotein comprised of five
extracellular cadherin-type repeats, one transmembrane region
and a highly conserved cytoplasmic tail [1,2]. E-cadherin is
expressed primarily in epithelial cells and is the major component
of Adherens Junctions (AJ). These junctions cluster, via homophilic
interactions, through the extracellular domains of calcium-
dependent E-cadherin molecules, on the surface of homotypic
neighbour cells.
The role of E-cadherin in tumour development is well
described, and its loss of expression is a hallmark in carcinomas
[3]. Experimental evidence supports a role for the E-cadherin
complex both in suppressing invasion and metastasis formation
[4]. Loss of E-cadherin expression is frequently associated to
genetic events such as splice site and truncation mutations caused
by insertions, deletions, and nonsense mutations, in addition to
missense mutations [5]. In sporadic diffuse gastric cancer,
alterations in the gene encoding E-cadherin (CDH1) are found
preferentially in exons 7 to 9 [5], while in lobular breast cancers
they are spread along the gene, with no preferential hotspot [6].
Missense mutations are found in these two types of sporadic cancer
and also in synovial sarcomas [7].
Familial aggregation of Diffuse Gastric Cancer (DGC) repre-
sents 10% of the cases of Gastric Cancer (GC), and only 1–3% are
hereditary [8]. From these familial cases, Hereditary Diffuse
Gastric Cancer (HDGC) is defined by stringent criteria that were
defined by the International Gastric Cancer Linkage Consortium
(IGCLC) in 1999: (1) two or more documented cases of diffuse
gastric cancer in first/second degree relatives, with at least one
diagnosed before the age of 50; or (2) three or more cases of
documented diffuse gastric cancer in first/second degree relatives,
independently of age. Early Onset Diffuse Gastric Cancer
(EODGC) is considered when an isolated individual is diagnosed
with DGC with less then 45 years of age. Germline CDH1
mutations are found in 30% of the HDGC cases [9]. The
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first described by Guilford et al in 1998 [10] and since then many
studies reported different types of CDH1 mutations in HDGC
[11,12,13]. Among all reported CDH1 germline mutations, 77.9%
are nonsense, splice-site and frameshift mutations (predicted to
produce premature termination codons) and 22.1% are missense
mutations [9]. Mutations that generate PTC are normally
deleterious, the patients are considered high risk carriers, and
are advised to have prophylactic total gastrectomy [14]. The
pathogenicity of missense mutations is not straightforward, and
these alterations are commonly referred as Unclassified Sequence
Variants (USVs) due to the lack of stringent criteria to evaluate
their impact. Several parameters have been taken into account for
the classification of E-cadherin USVs in HDGC: 1) co-segregation
of the mutation with DGC (within pedigrees); 2) mutation
frequency in the healthy control population; 3) mutation
recurrence (in independent families). Segregation analysis is often
impossible, with a small number of affected cases available for
molecular diagnosis [15], and the absence of clinical information is
a limiting step to infer the pathogenic significance of these
mutations. To circumvent this limitation we have previously
developed in vitro functional assays to evaluate the functional
impact of E-cadherin germline missense mutations [16,17].
However, such studies implicate lab specific experimental
conditions, namely cell biology assays, and they are time
consuming to use in routine. In silico predictions are reliable and
fast analysis that one can use to predict the impact of point
mutations, especially when structural information is available
[18,19].
In this work, we explored the potential of structure-based in silico
predictions to evaluate the impact of E-cadherin missense
mutations, found in hereditary and sporadic cancer. Our analysis
was based on the calculation of native-state stability changes
induced by each variant (DDG=DGWT2DGMut), obtained by the
protein design FoldX algorithm [20,21]. Interestingly, the group of
patients harbouring destabilizing mutations (DDG.0.8 kcal/mol)
is characterized by a younger age at diagnosis or death by DGC,
suggesting that the loss of E-cadherin native-state stability
contributes to the disease phenotype. Using a cellular model, we
analysed the phenotype of E-cadherin destabilization, and found
that when a mutation induces decreased native-state stability, E-
cadherin is prematurely degraded by the proteasome, exhibits
shorter half-life, resulting in loss of the adhesive function.
Altogether, our results suggest that destabilization accounts for
the pathogenicity of E-cadherin missense mutations found in
HDGC.
Materials and Methods
Collection of E-cadherin sequence variants and PDBs
E-cadherin variants associated to HDGC or EODGC were
collected from the literature, and somatic variants were collected
from the Catalogue of Somatic Mutations in Cancer (COSMIC)
database (http://www.sanger.ac.uk/genetics/CGP/cosmic/). Three
new E-cadherin sequence variants where reported to our lab for
functional analysis: E185V, S232C and L583R. Recently, L583R
was reported, with functional data associated [22].
E-cadherin-related PDBs were identified using automatic search
with Swiss Model Repository (http://swissmodel.expasy.org). Se-
quence alignment of human E-cadherin and each of the sequences
used for the different models was performed with M-coffee [23,
24] (http://tcoffee.crg.cat/apps/tcoffee/play?name=mcoffee). Imag-
es were prepared with Pymol. After analysing sequence and structural
homology, three PDBs were selected to use as models: Xenopus C-
cadherin ectodomain (PDB 1L3W), mouse E-cadherin prodomain
(PDB 1OP4) and the mouse b-catenin interacting domain (PDB
1I7X).
FoldX calculations and SIFT analysis
Using FoldX (http://foldx.crg.es/) command Buildmodel we built
three different models (prodomain, extracellular and cytoplasmic);
the three structures were humanized by substitution of each
different aminoacid. The resulting structure was optimized using
the command RepairPDB and the energies where analysed with
Stability or AnalyseComplex commands. The disease-associated
mutations were generated with the Buildmodel command, each
mutation repeated in five runs. The energies are an automatic
output in FoldX, and the native-state stability change, DDG,
between WT and mutant (DDG=DGWT2DGMut) is also
generated in a separate file, with the corresponding standard
deviations, and all the energetic penalties associated to each
mutation. Only mutations with DDG.0.8 kcal/mol were consid-
ered deleterious.
We used SIFT (http://sift.jcvi.org/, Sorting Intolerant From
Tolerant) to evaluate the conservation of each aminoacid
substitution, as previously described [25], using the Blink feature
of GI: 31073. Only mutations with a score below 0,05 were
considered to be Intolerant.
ProP (http://www.cbs.dtu.dk/services/ProP/) [26] was used to
evaluate if mutations could have an effect on prodomain cleavage.
Cell culture and transfections
E-cadherin WT cDNA was cloned in pIRES2-EGFP vector
according to manufacture instructions (Clontech, Takara Bio) and
mutations E185V, S232C, L583R and L583I hE-cadherin were
induced by site directed mutagenesis as described previously [27].
The empty vector (Mock) was used as control.
CHO (Chinese Hamster Ovary) cells (ATCC number: CCL-61)
were grown in Alfa-MEM medium (Gibco, Invitrogen) supple-
mented with 10% fetal bovine serum (FBS; Gibco, Invitrogen) and
1% penicillin-streptomycin (Gibco, Invitrogen). Cells were spo-
radically evaluated for mycoplasm contamination by imunofluor-
escence with DAPI. Cells were transfected with 1 ug of each of the
vectors encoding the different forms of E-cadherin (WT, E185V,
S232C, L583R and L583I) using Lipofectamine 2000 (Invitrogen),
according to the manufacture procedure. For stable cell line
establishment, cells were selected by antibiotic resistance to 5 mg/
ml blasticidin (Gibco, Invitrogen). All cell lines were maintained in
a humidified incubator with 5% CO2 at 37uC.
Functional assays
Transiently transfected CHO (Chinese Hamster Ovary) cells
(ATCC number: CCL-61) were subjected to flow citometry, using
GFP fluorescence measurement, to evaluate the transfection
efficiency before each experiment. For the slow aggregation assay,
wells of 96-well-plate were coated with 50 ml of agar solution
(100 mg Bacto-Agar in 15 ml of sterile PBS). Cells were detached
with trypsin and suspended in culture medium. A suspension of
1610
5 cells/ml was prepared and 2610
4 cells were seeded in each
well. The plate was incubated at 37uC in a humidified chamber
with 5% CO2 for 48 h. Aggregation was evaluated in an inverted
microscope (46 magnification) and photographed with a digital
camera.
Western blotting
Cell lysates were obtained with Catenin lysis buffer (1% Triton
X-100, 1% Nonidet P-40 in PBS), supplemented with protease
E-Cadherin Destabilization in Cancer
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(Sigma). Protein quantification was done by a modified Bradford
assay (Bio-Rad). For each sample, 25 mg of protein was loaded,
separated in 7.5% SDS-PAGE, and electroblotted to nitrocellulose
membrane (GE Healthcare Life Sciences). Membranes were
blocked with 5% non-fat dry milk and 0.5% Tween-20 in PBS.
Immunoblotting was performed with antibodies against E-
cadherin (1:1000; BD Biosciences), actin (1:1000; Santa Cruz
Biotechnology), and a-tubulin (1:10000; Sigma). Sheep anti-mouse
(GE Healthcare Life Sciences) or donkey anti-goat (Santa Cruz
Biotechnology) were used as secondary antibodies, followed by
ECL detection (GE Healthcare Life Sciences). Immunoblots were
quantified in Quantity One software (Bio-Rad).
Fluorescence-activated cell sorting (FACS)
Cells were grown to a confluent monolayer, detached with
Versene (Gibco, Invitrogen) and resuspended in ice cold PBS with
0.05 mg/ml CaCl2. A suspension of 5610
5 cells was centrifuged
for 5 minutes at 1500 rpm 4uC, and washed in PBS with
0.05 mg/ml CaCl2 3%BSA. Cells were incubated for 60 minutes
with a primary antibody against E-cadherin, HECD1 (Zymed
Laboratories) at 1:100 dilution. Cells were washed twice and then
incubated with anti-mouse biotinilated (Dako) at 1:100 dilution.
Cells were washed twice and then incubated with streptavidin PE-
CY5 (BD Pharmingen) at 1:40 dilution. Finally, cells were washed,
resuspended in 500 ml of PBS, and 50000 cells were analyzed in a
flow cytometer (Coulter Epics XL-MCL). Data was analyzed with
WinMDI software.
Immunofluorescent staining
For Immunofluorescence and microscopy, cells were seeded on
glass coverslips and grown to about 80% confluence, fixed in ice-
cold methanol for 15 minutes, washed 2 times with PBS, and
incubated with primary antibody, diluted in PBS 5%BSA, for
60 minutes at room temperature. Primary antibodies used: mouse
monoclonal anti-E-cadherin (BD Biosciences); rabbit anti-Cal-
nexin (Stressgen). Secondary antibodies used: Alexa Fluor 488
anti-mouse (1:500; Invitrogen); Alexa Fluor 594 anti-rabbit (1:500;
Invitrogen). The coverslips were mounted on glass slides, using
Vectashield with DAPI for nuclear detection (Vector Laborato-
ries). Image acquisition was performed on Carl Zeiss Apotome
Axiovert 200 M Fluorescence Microscope using 406 objectives.
Images were acquired with Axiocam HRm camera and processed
by software Axiovison version 4.8.
Cell Treatments
For the protein synthesis inhibition, cells were treated with
25 mM of Cycloheximide for 8 h and 16 h, and the amount of
total E-cadherin was analyzed by WB as described previously. For
the proteasome inhibition assay, cells were seeded in 6 well plates,
grown to approximately 80% of confluence, and incubated for
16 h with 10 mM MG132 (CalBioChem). Cell lysates were
analysed by WB as described previously.
Results
1. E-cadherin structural models
There are few human E-cadherin (hE-cad) structures available,
and they only cover small portions of the protein (Table S1). Using
automatic search of Swiss Model Repository, we found that PDB
1L3W, annotated for the full length extracellular domain of
xenopus EP-cadherin (EP-cad), is highly homologous to the same
domain in human E-cadherin. We analysed sequence homology
by alignment using M-coffee, a multiple sequence alignment that
combines the output of several multiple sequence alignment
packages (PCMA, Poa, Mafft, Muscle, T-Coffee, ClustalW,
ProbCons, DialignTX) [23,24]. Figure 1A shows the alignment
of the two extracellular domain sequences. The red brick regions
represent perfect agreement among the methods used, represent-
ing highly similar sequences. To build the model structure, we
removed regions with no similarity (Figure 1A, stars), and limited
the model to regions with reliable alignment (black arrow,
Figure 1A). The xenopus structure was humanized as described
in Material and Methods and Figure 1B shows the structural
alignment of hE-cad EC1–EC2 domains (from PDB 2O72) and
EC1–EC2 domains of the xenopus derived structural model. The
two structures are nearly superimposed, indicating that the
similarity between the extracellular domains of human E-cadherin
and xenopus EP-cadherin is not only at the sequence level but also
at the structural level. The model structure of human E-cad
exhibits compatible energies with the structure from xenopus, with
a slight decrease of free energy (DG) obtained for the model
(DGreal=559.99 kcal/mol and DGmodel=531.77 kcal/mol), indi-
cating that the humanization doesn’t introduce extra clashes.
Recently, a structure of the mouse extracellular domain was
released (PDB 3Q2V, Table S1), and we also used this structure as
a model, as a way to refine the results obtained with the xenopus
model.
We established two other models, covering the Prodomain (PDB
1OP4, from mouse N-cadherin) and the b-catenin cytoplasmic
domain (PDB 1I7X, from mouse E-cadherin), using the same
methodology. Altogether, the three models cover most of the
protein structure (Figure 1C): the prodomain model covers
positions 28–117, the extracellular models positions 155–697
and the b-catenin cytoplasmic domain covers 782–838. At the
level of the juxtamembrane domain, one structure is annotated,
comprising the interacting surface between E-cadherin and p120
[28]. This structure contains a small, 18 aminoacids long peptide
(covering positions 756–773 on hE-cad), with very low structural
content, factors that decrease the reliability of the energy
calculations, so we discarded this structure from the analysis.
2. In silico prediction of the impact of cancer-associated
E-cadherin USVs
E-cadherin mutations are not only the genetic cause of HDGC,
but they are also frequently found in different types of sporadic
cancers. We analyzed in silico the impact of all cancer-associated E-
cadherin missense mutations that localize to the regions covered
by the structural models generated: 22 germline mutations found
in the settings of HDGC and EODGC, and 57 found in sporadic
cancers. Germline E-cadherin USVs were collected from the
literature, and some are personal communications of our lab.
Some HDGC/EODGC mutations are not possible to model, due
to the lack of structural information (e.g. the ones localized in the
juxtamembrane domain of E-cadherin), and were not included in
this analysis. Somatic mutations were collected from the Cancer
Genome Project database, and contain mutations found in gastric
and lobular breast cancer (the only two types of cancer associated
to HDGC), but also other types of cancer such as synovial sarcoma
or bile duct carcinoma (Table S2).
Using the structural models described previously, we used
FoldX to generate each of the cancer associated USVs, and
evaluated their native-state stability, DG (commonly referred
as total energy for simplicity) [20]. The energetic difference
between the WT reference and the corresponding mutant
(DDG=DGWT2DGMut) was calculated for the 22 HDGC/
EODGC E-cadherin USVs localized to the regions covered by
the model structures, and the results are listed in Table 1. When
E-Cadherin Destabilization in Cancer
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mutant form; when it is positive, it implies that the mutant is less
stable then the WT reference. Previous studies in other proteins
have shown that stability changes calculated with FoldX algorithm
below 0.8 kcal/mol are within the error change of the software,
and are thus considered to be non-significant [21]. Accordingly,
we only considered mutations to be destabilizing when they induce
energy changes above 0.8 kcal/mol. In Figure 2A, mutations
above the scheme are destabilizing, while the bottom ones are
structurally tolerated. It is clear that destabilizing mutations are
spead along the protein, with no preferential domain affected.
The prodomain of hE-cad is cleaved during maturation, and if
this is not accomplished, E-cadherin adhesive function is impaired
[29,30]. For the mutations localized in this domain, we evaluated
the impact in total energy with FoldX, the conservation with
SIFT, and also evaluated if the interference with the prodomain
Figure 1. E-cadherin structural models. A) Sequence alignment of the extracellular domains of human E-cad and xenopus EP-cad. The
extracellular sequences were obtained in Uniprot with the corresponding references (human E-cadherin, P12830; xenopus EP-cadherin, P33148). M-
Coffee regular was used to perform the alignment, a package that combines different alignment methods. Red brick regions are in perfect agreement
across all the methods, green and yellow regions are regions of no agreement between the different alignment methods. The average consistency
score obtained was 98, confirming the reliability of the alignment. The blue stars identify the aminoacids that were removed from the 1L3W structure
before humanizing. The black arrow indicates the end of the structural model obtained. B) The human structure of domains EC1-EC2 (PDB 2O72, blue)
was aligned with the same domains of the human model generated from the xenopus structure (PDB 1L3W, red). Image created with Pymol. C)
Schematic representation of human E-cadherin domains, highlighting the coverage of the three different structural models obtained with FoldX
(models of prodomain, extracellular domain and the Catenin Binding Domain).
doi:10.1371/journal.pone.0033783.g001
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found that both hereditary (G62V and T118R) and sporadic
(P30T, G62D, H92Y, H121R and H123Y) mutations localized in
E-cadherin prodomain are structurally tolerated, as predicted by
FoldX (Table S3). When we analyse the impact based on
conservation using SIFT, we also found that none of the mutations
was considered deleterious, because their degree of conservation is
low (Table S3). These results indicate that the pathogenicity of E-
cadherin USVs localized in the prodomain is likely not dependent
on destabilization. We also found no effect on the cleavage of the
propeptide, as predicted by ProP (data not shown). Accordingly,
we believe that the pathogenicity of E-cadherin mutations in this
domain can result from the interference with the docking of
proteins involved in prodomain processing, impossible to predict in
silico.
Hereditary E-cadherin USVs span the full length of the
extracellular domain, while sporadic mutations are predominantly
found in EC2–EC3, as in accordance with the hotspot previously
described in exons 7–9 [5]. From the total 18 germline HDGC/
EODGC mutations localized in this domain, we found that 10
have a significant structural impact in the protein (Table 1).
Approximately half of the sporadic mutations are also destabilizing
(Table S3), independently of the EC domain where they are
localized, suggesting that native-state destabilization may be
associated to a substantial fraction of sporadic cancers involving
E-cadherin loss by point mutation.
Only three mutations are localized in the region mapped by the
model of the cytoplasmic b-catenin binding domain (P799R,
V832M, S838G): the first two identified in the HDGC/EODGC
setting and the other one sporadic, found in ovary carcinoma [31].
For these mutations we analysed the binding energy between E-
cadherin and b-catenin and found that none of them significantly
alters the binding affinity of b-catenin, according to FoldX
prediction. This is in accordance with the in vitro results showing
that the hereditary mutation V832M efficiently binds b-catenin,
and its pathogenicity seems to be dependent on the inability of the
E-cadherin/b-catenin complex to bind a-catenin [32,33].
We collected all the predictions and functional in vitro data of
HDGC/EODGC mutations and analysed the reliability of the
predictors used (Table 1). We classified the results from the
predictions as: True Positive (TP) when the mutation is predicted
as deleterious in silico (either by FoldX or SIFT) and exhibit loss of
function in vitro; True Negative (TN) when the mutation is
predicted as tolerated in silico and is functional in vitro; False
Positive (FP) when the mutation is predicted as deleterious in silico
but is functional in vitro; and False Negative (FN) when the
Table 1. In silico based analysis of the impact of HDGC-associated E-cadherin missense mutations.
Aminoacid Alteration Genetic Alteration DDG SIFT Score In vitro Function FoldX SIFT Reference
G62V c.185G.T 20,45 0,14 ND - - [41]
T118R c.353C.G 20,32 0,45 Loss FN FN [42]
P172R c.515C.G 0.8 0 ND - - [43]
L214P c.641T.C 70L o s s T PT P ( c )
G239R
a c.715G.A 2,56 0 Loss TP TP [42]
D244G
a c.731A.G 0,15 0,14 ND - - [44]
A298T c.892G.A 8,31 0,01 Loss TP TP [13]
T340A c.1018A.G 1,09 0,08 Loss TP FN [45,46]
P373L c.1118C.T 1,12 0 Loss TP TP [47]
W409R c.1225T.C 20,24 0 Loss FN TP [13]
I415L c.1243A.C 20,9 0,01 ND - - [48]
P429S c.1285C.T 1,56 0,02 Loss TP TP [49]
V487A c.1460T.C 0,45 0,56 ND - - [44]
A592T
b c.1774G.A 3,42 0 Functional FP FP [50,51]
T599S c.1796C.G 0,22 0,2 ND - - [45]
A617T
b c.1849G.A 0,06 0,43 Functional TN TN [17]
A634V
a c.1901C.T 1,05 0,26 Loss TP FN [17,52]
P799R c.2396C.G 0,62 0,03 Loss FN TP [50]
V832M c.2494G.A 21,1 0 Loss FN TP [16,53]
E185V c.554A.T 0,29 0,25 Functional TN TN (d)
S232C c.695C.G 20,9 0,01 Functional TN FP (d)
L583R c.1748T.G 2,72 0 Loss TP TP [22]
Only mutations that localize in the domains covered by the structural models are listed. FoldX calculations are reflected by the value of native-state stability changes
(DDG=DGWT2DGMut), expressed in kcal/mol. Mutations associated to structural impact present DDG.0,8 kcal/mol in the FoldX column, and values below 0,05 in the
SIFT column are considered to be intolerant due to high conservation. Predictions were scored as: True Positive (TP) when the software predicts high impact and the
mutants exhibits in vitro loss of function; True Negative (TN) when the software predicts no impact and the mutant is functional in vitro; False Positive (FP) when the
software predicts high impact but the mutant is functional in vitro; and False Negative (FN) when the software predicts no impact and the mutant exhibits in vitro loss
of function. Only mutations that have been functionally characterized in vitro are classified. The mutations that have been described to impact the splicing pattern are
depicted with (a). Mutations found at a frequency higher than 1% in one control population are considered polymorphisms, and marked with (b). Mutations published
as personal communications are referenced with (c). The newly identified mutations are listed in the bottom of the table, unpublished are marked with a (d). ND – Not
Determined.
doi:10.1371/journal.pone.0033783.t001
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mapping all the modelled germline mutations found in the setting of HDGC or EODGC. Above the scheme are the mutations that resulted in
destabilization, as predicted by FoldX (DDG.0.8 kcal/mol) and below the scheme all the non-destabilizing mutations (DDG,0.8 kcal/mol). The newly
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function. TP and TN are positive results, meaning that the
predictors are able to detect the mutation impact in function; FP
and FN represent their degree of failure. We found that both
algorithms are able to predict the functional impact of up to 70%
of the germline HDGC/EODGC mutations (11 out of 16
mutations), with predictions overlapping for half of the mutations
(Table 1, Figure 2B).
We analysed the data available for the germline HDGC/
EODGC mutations carriers and, although the information is
limited, we found that the most complete set of data is the age of
onset or death associated to DGC. When we box-plot this data,
grouping ‘‘Destabilizing’’ and ‘‘Non-destabilizing’’ mutation
carriers, we observe an evident younger age of disease onset
(diagnosis or death) for the first group (Figure 2D), suggesting that
native-state destabilization accounts for the earlier development of
DGC.
3. Biological significance of E-cadherin destabilization
To determine the biological significance of E-cadherin desta-
bilization, we used as model system three newly identified E-
cadherin germline missense mutations reported to our lab for
functional characterization: E185V, S232C and L583R, the later
recently described in the literature [22]. The in silico analysis
described previously was performed for these three new mutations
and the results are included in Table 1 (below the dark line).
Mutations E185V and S232C are structurally tolerated, with
DDG=0.29 kcal/mol and 20.9 kcal/mol respectively (Table 1),
considered insignificant regarding the impact in structure.
Mutation S232C promotes a decrease in energy, stabilizing the
protein, and this is due to the loss of the high energy of a Serine
buried OH group, which is not involved in an H-bond, and to the
accommodation of the sidechain of Cysteine. Mutation L583R
induces destabilization, with DDG=2.72 kcal/mol, reflecting the
dramatic change from a hydrophobic to hydrophilic aminoacid,
that results in an Arginine not able to form H-bonds, being
unfavourably buried.
In vitro functional assays were performed for the above-
mentioned HDGC/EODGC mutations, and we found a perfect
correlation between the functionality in vitro and the presence/
absence of structural impact: E185V and S232C retain the
adhesive function of E-cadherin, and are able to form tight cellular
aggregates, while L583R exhibits a clear scattered pattern,
resembling Mock cells (Figure 3A), indicating that E185V and
S232C are non-pathogenic and L583R is pathogenic.
When we analysed E-cadherin expression in the different cell
lines, we found that the total amount of mutant L583R is lower
that the WT expression under the same conditions, while
mutations E185V and S232C, retain normal levels (Figure 3B).
Interestingly, the band corresponding to L583R is retained in the
gel, indicating that L583R is not able to properly mature
(immature form of E-cadherin is 130 kDa, mature is 120 kDa)
and flow cytometry results show that it is less expressed in the
plasma membrane (Figure 3C).
When protein maturation fails, this commonly results in
Endoplasmic Reticulum (ER) retention of immature protein. To
test whether L583R was indeed retained as immature, we analysed
if it is retained in the ER by co-immunofluorescence with the ER
marker calnexin (Figure 4A), and found that part of the L583R
signal is superimposed with the ER marker, indicating increased
ER retention.
To understand if destabilization could be detected in vitro,w e
analysed the stability of L583R in the cell, evaluating its turnover.
We blocked protein synthesis with cycloheximide and found that
L583R is soon degraded, as evaluated by its residual expression
soon after 8 h of protein synthesis inhibition, in contrast to WT
and the other mutants that are still highly expressed in the same
condition (Figure 4B), indicating that L583R is unstable in the cell.
The presence of immature band in WT or mutant E-cadherin
samples (top band, Figure 4B) is due to the overload of protein
resulting from transient transfection.
Unstable or misfolded proteins are tightly regulated by Protein
Quality Control mechanisms that protect the cell by directing
newly synthesized unfolded proteins for degradation in the
proteasome [34]. To address if this is the case for L583R, we
inhibited the proteasome activity with MG132 and observed that,
despite the different initial levels of E-cadherin, the expression of
mutant L583R is completely restored upon treatment (Figure 4C),
indicating that it is prematurely degraded by the proteasome after
synthesis, as previously described for other juxtamembranar
HDGC-associated E-cadherin mutations [35]. Interestingly, when
proteasome degradation is inhibited, there is an accumulation of
immature E-cad in all cell lines, manifesting the importance of the
proteasome in the regulation of newly synthesized E-cad,
independently of being mutated or not.
To further validate the in silico predictions, we analysed the
phenotype of a reverted destabilized mutation by inducing a
structurally tolerated alteration in the same position of the
mutant form of E-cadherin. Using FoldX, we calculated the
impact of each possible alteration in position 583 and found
that the alteration inducing less destabilization was L583I
(DDG=0.56 kcal/mol, as predicted using the mouse model,
Table S3). Interestingly, this mutation retains the adhesive
function of E-cadherin, resulting in compact cell aggregates
(Figure 4D), and is not destabilized in vitro, exhibiting ciclohex-
imide resistance comparable to the WT form (Figure 4E). These
results emphasize the reliability of the in silico based predictions of
E-cadherin stability and the clear association of E-cadherin
destabilization with loss of adhesive function.
Discussion
E-cadherin alterations (mutations, deletions and methylation)
are the only recognized genetic cause of HDGC [36,37,38]. Most
mutations identified in HDGC are of the nonsense type, but a
identified mutations are underlined. B) FoldX and SIFT were used to evaluate the impact of the mutations present in A) and the predictions were
classified as: True Positive (TP) when the software predicts high impact and the mutants exhibit in vitro loss of function; True Negative (TN) when the
software predicts no impact and the mutant is functional in vitro; False Positive (FP) when the software predicts high impact but the mutants is
functional in vitro; and False Negative (FN) when the software predicts no impact and the mutants exhibits in vitro loss of function. The results from
both predictors result in 70% overlap with E-cadherin protein function tested in vitro (TP+TN). C) Box-plot representing the median and interquartile
ranges of the native-state stability changes (DDG) of the Destabilizing and Non-destabilizing mutations, as predicted by FoldX. D) Box-plot
representing the median and interquartile ranges of ages of Gastric Cancer detection or associated death, corresponding to the Destabilizing and
Non-destabilizing mutations carriers. All the data was collected from the literature. The group of patients harbouring destabilizing mutations is
characterized by a clear younger age of diagnosis or death, suggesting the contribution of E-cadherin destabilization for the disease phenotype.
doi:10.1371/journal.pone.0033783.g002
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single aminoacid substitutions, of which the pathogenicity is
difficult to evaluate and is often unclear [39,40]. The most
important information in terms of genetic counselling of germline
missense mutation carriers is familial clinical information (segre-
gation analysis, mostly) but this information is often scarce with the
size of the pedigree commonly being too small to allow segregation
studies, and the pathogenicity assessment usually comes from cell-
based in vitro functional assays [15,17], which are time consuming
and technically demanding, and are therefore not widely
applicable in routine molecular labs. Consequently, there is a
need for new methods to determine the pathogenicity of E-
cadherin missense mutations associated to HDGC [40]. Our
group has previously described a model to infer the pathogenicity
of this type of mutation, based on different variants such as co-
segregation of the mutation within pedigrees, frequency in healthy
population, recurrence in independent families, and functional in
vitro and in silico data [15]. In that case, the structural in silico
analysis was limited to the EC1–EC2 domains, and was thus
incomplete. In this work we used FoldX to generate structural
models covering the major part of E-cadherin (Figure 1C),
calculate the energetic penalty induced by each mutation, and
compare the results with in vitro and in vivo phenotypes.
We have previously showed that E-cadherin folding is surveyed
by mechanisms of Protein Quality Control and that HDGC-
associated mutations can be prematurely degraded by the
Endoplasmic Reticulum Associated Degradation (ERAD), a
mechanism responsible for the clearance of misfolded and unstable
proteins, dependent on the proteasome [35]. These results strongly
suggest that some E-cadherin missense mutations may have
structural impact, resulting in protein misfolding. To evaluate if
each mutation impacts the structure and stability of E-cadherin,
we based our analysis in the calculation of native-state stability
changes (DDG) using FoldX algorithm. We evaluated 22 germline
HDGC/EODGC and 57 sporadic E-cadherin missense mutations
regarding structural impact (FoldX) and evolutionary conservation
(based on SIFT analysis) and found that the destabilizing
mutations span the full length of the extracellular domain, with
no hotspot for a particular domain. Most HDGC/EODGC
mutations (16 out of 22) are functionally characterized in vitro,s o
we used this information to evaluate the power of the predictors to
infer loss of function. Using a simple classification of the results
obtained with FoldX and SIFT (True Positive, True Negative,
False Positive and False Negative), we found that both predictors
accurately predict around 70% of the functional impact of the
mutations (TP plus TN); with FoldX, we found that loss of
function correlates with loss of native-state stability for half of the
analysed mutations (8 out of 16), with most of them also being
highly conserved (6 out of 8). Interestingly, when we analysed the
mutation carriers in detail, we found that the group of patients
harbouring Destabilizing mutations is characterized by the
development of disease at a younger age, when compared to the
group with mutations that keep native-state stability (Figure 2D).
These results indicate that not only E-cadherin native-state
stability is frequently disturbed by germline mutations, but also
that destabilization accounts for the disease phenotype, inducing
earlier development of disease. It would be informative if
imunohistochemistry of E-cadherin in DGC was compared
between carriers of ‘‘Destabilizing’’ and ‘‘Non-destabilizing’’
mutations, but we didn’t have enough material to analyze this
parameter in depth. Additionally, the percentage of destabilizing
sporadic mutations is also high (around 40%), suggesting that
destabilization may also account for the loss of E-cadherin
function in sporadic cancer.
Furthermore, we wanted to analyse if E-cadherin structural
destabilization induced by missense mutations was correlated to
misfolding in the cell and recognition by ERAD, resulting in loss of
expression. We used three newly identified germline mutants
Figure 3. Functional impact of three new HDGC-associated E-cadherin missense mutations: E185V, S232C and L583R. CHO cells were
transiently (A) or stably (B–C) transfected with an empty vector (Mock) or WT, E185V, S232C, L583R E-cadherin cDNA. A) Functional aggregation assay
was performed as described in Material and Methods. L583R cells show E-cadherin loss of function, resulting in a scattered pattern, resembling Mock
cells. DDG was calculated using FoldX algorithm and is 0 for the WT reference; B) Total cell lysates were prepared and E-cadherin was detected by
Western Blot using anti-E-cadherin antibody. Anti-a-Tubulin antibody was used as a loading control. The expression of L583R is reduced and shifted
to higher molecular weight, indicative of being retained as immature (approximately 130 kDa). C) E-cadherin expression in the Plasma Membrane
(PM) was evaluated using Flow Cytometry, after staining with an extracellular anti-human E-cadherin antibody. L583R is less expressed in the PM.
doi:10.1371/journal.pone.0033783.g003
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impact in silico with FoldX and SIFT, and in vitro, characterizing
expression, subcellular localization and degradation pattern. We
found that only mutation L583R induces high impact in the
structure (DDG=2,7 kcal/mol) besides being totally conserved. In
vitro functional assays indicate that L583R is pathogenic, exhibiting
loss of adhesive function (scattered cell pattern), in contrast to
E185V and S232C that retain adhesive function (Figure 3). We
found that L583R is less expressed due to maturation deficiency,
accumulates in the ER, is prematurely degraded by the
proteasome, and exhibits high turnover and shorter half-life,
indicating that it is regulated by ERAD (Figure 4). Interestingly, if
we introduce a structurally tolerated alteration in the same
position (L583I, as predicted by FoldX), the function is recovered
and stability is restored, resulting in an increased in half-life of the
protein (Figure 4D–E). This result shows the direct correlation
between in silico predicted destabilization and decreased E-
cadherin half-life.
Overall, our results indicate that E-cadherin missense mutations
found in cancer frequently lead to native-state destabilization, and
we show that the carriers of destabilizing mutations develop DGC
earlier in life, suggesting that this subset of mutations is more
pathogenic.Invitrostudiesshowthatstructuraldestabilizationresults
in high turnover in the cell, recognition by ERAD, premature
degradation by the ubiquitin-proteasome system and consequent
loss-of-function. We propose for the first time that E-cadherin
destabilization accounts for HDGC pathogenicity, and that in the
absence of clear clinical observations, in silico predictions should be
Figure 4. ERAD is involved in the regulation of E-cadherin destabilizing mutations. CHO cells were stably (A, C) or transiently (B, D, E)
transfected with an empty vector (Mock) or WT, E185V, S232C, L583R, L583I E-cadherin cDNA. A) E-cadherin and Calnexin immunofluoresce was
performed in stable CHO cells expressing WT and L583R. Calnexin was used as an ER marker. L583R is retained in the ER, as evaluated by the
colocalization with calnexin (yellow and arrows). B) Protein synthesis was blocked with Cicloheximide for 8 h and 16 h, to analyse E-cadherin
turnover. E-cadherin was detected by Western Blot using anti-E-cadherin antibody and anti-a-Tubulin antibody was used as a loading control. L583R
exhibits higher turnover. C) Cells were incubated with proteasome inhibitor MG132 for 16 h, and total cell lysates were prepared and analyzed.
Proteasomal degradation results on the accumulation of L583R to levels similar to WT, indicating that the proteasome is necessary for the mutant
downregulation. D) Functional aggregation assay was performed as described in Material and Methods. Cells expressing the artificial mutant L583I
recover E-cadherin adhesive function, resembling WT cells, in contrast to L583R, which are not able to perform adhesion. E) Protein synthesis was
blocked with Cicloheximide for 8 h and 16 h, to analyse E-cadherin turnover. In contrast to the unstable L583R, the stable mutation (L583I) is resistant
to protein synthesis blockage, exhibiting lower turnover, comparable to the WT protein. The two bands of E-cad in B) and E) correspond to mature
(lower, 120 kDa) and immature (upper, 130 kDa) forms of the protein, and result from the overload of protein commonly observed upon transient
transfections.
doi:10.1371/journal.pone.0033783.g004
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tolerated E-cadherin variants associated to HDGC or EODGC.
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